The $2 billion medical imaging company and ASX market darling transformed itself in the space of 48 hours this week, with a geography expanding acquisition and a major product release.
4DMedical
ASX:4DX
A slew of ASX listed biotech and critical minerals names could lose millions due to changes in R&D incentives that have sparked concerns across the wider innovation community.
The medical imaging company has experienced a run for the ages, with the stock up 2,000% in the ASX in less than a year. Not everyone is convinced it can continue.
A “not financially material” contract with the influential Mayo Clinic triggered another surge in the medtech’s share price. Naysayers are starting to doubt themselves.
After a transformative run of regulatory wins and commercial deals, the company has secured the backing of major investors in the first big equity raise of the year led by Bell Potter.
The $2.3b market darling is expected to raise $150m after an extraordinary 5-month share price surge, but investors are split on whether the dream run can continue.
The market darling's results will take centre stage, but a bet on an ASX minnow has set tongues wagging at the smaller end of the market.
